ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

GM Honors Blackburn, Kuhl, Phelps, Speizer, And Willett

June 8, 2001

Big Get Bigger, Litton Primate Contract Renewed

September 19, 1975

Adjuvant Nutrition Breast Cancer Study Offered To Groups

March 19, 1982

NCA Uneasy Over Possible NIH Takeover Of FCRC, But It Won’t Happen

June 13, 1980

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

July 28, 1989

ACS Executive Proposes Efficiency Plan, Critics Fear Erosion Of Local Influence

May 1, 1998